Summary
Global Markets Direct’s, ‘Diabetic Neuropathy - Pipeline Review, H1 2016’, provides an overview of the Diabetic Neuropathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy
- The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Achelios Therapeutics, Inc.
Araim Pharmaceuticals, Inc.
Celgene Corporation
Commence Bio, Inc.
Glenmark Pharmaceuticals Ltd.
Glucox Biotech AB
Kineta, Inc.
Lpath, Inc.
Neuralstem, Inc.
NovaLead Pharma Pvt. Ltd.
Omeros Corporation
PhiloGene, Inc.
Reata Pharmaceuticals, Inc.
Relief Therapeutics S.A.
Sucampo Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
ViroMed Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathy - Overview 10
Pipeline Products for Diabetic Neuropathy - Comparative Analysis 11
Diabetic Neuropathy - Therapeutics under Development by Companies 12
Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Neuropathy - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diabetic Neuropathy - Products under Development by Companies 18
Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20
Diabetic Neuropathy - Companies Involved in Therapeutics Development 21
Achelios Therapeutics, Inc. 21
Araim Pharmaceuticals, Inc. 22
Celgene Corporation 23
Commence Bio, Inc. 24
Glenmark Pharmaceuticals Ltd. 25
Glucox Biotech AB 26
Kineta, Inc. 27
Lpath, Inc. 28
Neuralstem, Inc. 29
NovaLead Pharma Pvt. Ltd. 30
Omeros Corporation 31
PhiloGene, Inc. 32
Reata Pharmaceuticals, Inc. 33
Relief Therapeutics S.A. 34
Sucampo Pharmaceuticals, Inc. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
ViroMed Co., Ltd. 37
Diabetic Neuropathy - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
atexakin alfa - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
benfotiamine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BNV-222 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
cibinetide - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CMB-200 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Cyndacel-M - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Flexicaine Peel - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GRC-17536 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ketoprofen - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Lpathomab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ND-07 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NLP-198 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NSI-566 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
OMS-721 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PDA-002 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pirenzepine hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ranirestat - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RTA-901 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
RTU-1096 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule for Pain - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules for Diabetic Neuropathy - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
U-2902 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
VM-202 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Diabetic Neuropathy - Recent Pipeline Updates 88
Diabetic Neuropathy - Dormant Projects 108
Diabetic Neuropathy - Discontinued Products 112
Diabetic Neuropathy - Product Development Milestones 113
Featured News & Press Releases 113
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 113
Sep 17, 2014: Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 114
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 115
May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 115
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 116
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 116
Sep 29, 2005: Dainippon And Eisai Signs Licensing Agreement For A Potential New Treatment For Diabetic Neuropathy 116
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 118
Disclaimer 119
List of Tables
Number of Products under Development for Diabetic Neuropathy, H1 2016 10
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H1 2016 21
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H1 2016 22
Diabetic Neuropathy - Pipeline by Celgene Corporation, H1 2016 23
Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H1 2016 24
Diabetic Neuropathy - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 25
Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H1 2016 26
Diabetic Neuropathy - Pipeline by Kineta, Inc., H1 2016 27
Diabetic Neuropathy - Pipeline by Lpath, Inc., H1 2016 28
Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H1 2016 29
Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 30
Diabetic Neuropathy - Pipeline by Omeros Corporation, H1 2016 31
Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H1 2016 32
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 33
Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H1 2016 34
Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 35
Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 36
Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2016 37
Assessment by Monotherapy Products, H1 2016 38
Number of Products by Stage and Target, H1 2016 40
Number of Products by Stage and Mechanism of Action, H1 2016 42
Number of Products by Stage and Route of Administration, H1 2016 44
Number of Products by Stage and Molecule Type, H1 2016 46
Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016 88
Diabetic Neuropathy - Dormant Projects, H1 2016 108
Diabetic Neuropathy - Dormant Projects (Contd..1), H1 2016 109
Diabetic Neuropathy - Dormant Projects (Contd..2), H1 2016 110
Diabetic Neuropathy - Dormant Projects (Contd..3), H1 2016 111
Diabetic Neuropathy - Discontinued Products, H1 2016 112
List of Figures
Number of Products under Development for Diabetic Neuropathy, H1 2016 10
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 38
Number of Products by Top 10 Targets, H1 2016 39
Number of Products by Stage and Top 10 Targets, H1 2016 39
Number of Products by Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Routes of Administration, H1 2016 43
Number of Products by Stage and Routes of Administration, H1 2016 43
Number of Products by Molecule Types, H1 2016 45
Number of Products by Stage and Molecule Types, H1 2016 45
